A conserved multi-gene family induces cross-reactive antibodies effective in defense against Plasmodium falciparum.
BACKGROUND
Two related merozoite surface proteins, MSP3 and MSP6, have previously been identified as targets of antibody-dependent cellular inhibition (ADCI), a protective mechanism against Plasmodium falciparum malaria. Both MSP3 and MSP6 share a common characteristic small N-terminal signature amino-acid stretch (NLRNA/G), a feature similar to MSP3-like orthologs identified in other human and primate malaria parasites.


RESULTS
This signature amino-acid sequence led to the identification of eight ORFs contiguously located on P. falciparum chromosome 10. Our subsequent investigations on their expression, localization, sequence conservation, epitope sharing, immunogenicity and the functional role of antibodies in defense are reported here. Six members of P. falciparum MSP3-multigene family share similar sequence organization within their C-terminal regions, are simultaneously expressed as merozoite surface proteins and are highly conserved among parasite isolates. Each of these proteins is a target of naturally occurring antibodies effective at parasite killing in ADCI assays. Moreover, both naturally occurring antibodies and those generated by immunization display cross-reactivity with other members of the family and exhibit varied binding avidities.


CONCLUSIONS
The unusual characteristics of the MSP3 multi-gene family lead us to hypothesize that the simultaneous expression of targets eliciting cross-reactive antibody responses capable of controlling parasite densities could represent an immune process selected through evolution to maintain homeostasis between P. falciparum and human hosts; a process that allows the continuous transmission of the parasite without killing the host. Our observations also have practical consequences for vaccine development by suggesting MSP3 vaccine efficacy might be improved when combined with the various C-terminus regions of the MSP3 family members to generate a wider range of antibodies acting and to increase vaccine immunogenicity in varied human genetic backgrounds.
Singh
Subhash
S
Bio-medical Parasitology Unit, Institut Pasteur, Paris, France. subhash.singh@gennova.co.in
Soe
Soe
S
Weisman
Simon
S
Barnwell
John W
JW
Pérignon
Jean Louis
JL
Druilhe
Pierre
P
D000818:Animals; D000913:Antibodies, Protozoan / Q000276:immunology*; D000917:Antibody Formation / Q000235:genetics*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology; D000953:Antigens, Protozoan / Q000276:immunology*; D017124:Conserved Sequence; D003429:Cross Reactions / Q000276:immunology*; D006801:Humans; D008565:Membrane Proteins / Q000276:immunology; D005810:Multigene Family / Q000276:immunology; D010963:Plasmodium falciparum / Q000276:immunology*; D015800:Protozoan Proteins / Q000276:immunology*
D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D008565:Membrane Proteins; D015800:Protozoan Proteins; C089133:merozoite surface protein 3, Plasmodium; C435213:merozoite surface protein 6, Plasmodium